

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A method for ~~treating~~ inhibiting or preventing a T cell mediated autoimmune response associated with type I diabetes disorder comprising administering to ~~the~~ a subject in need of such treatment a therapeutically or prophylactically effective amount of an gp39 antagonist of a receptor on a surface of a T cell which mediates contact dependent helper effector functions selected from the group consisting of soluble CD40, CD40 fusion protein, and an anti-gp39 antibody or a fragment thereof that binds gp39.

Claims 2-3 (canceled)

Claim 4 (currently amended): The method of claim 1, wherein the ~~receptor on the surface of the T cell which mediates contact dependent helper effector function is~~ gp39 antagonist is a fragment of an anti-gp39 antibody that binds gp39.

Claim 5 (currently amended): The method of claim 4, wherein the gp39 antagonist is an anti-gp39 antibody.

B3
Claim 6 (original): The method of claim 5, wherein the anti-gp39 antibody is a monoclonal antibody.

Claim 7 (original): The method of claim 5, wherein the anti-gp39 antibody is an anti-human gp39 antibody.

Claim 8 (currently amended): The method of claim 6, wherein the monoclonal antibody is ~~produced by 89-76 hybridoma, ATCC Accession Number HB11713 or 24-31 hybridoma, ATCC Accession Number HB 11712 ,~~ or an antibody having the gp39 binding characteristics thereof.

Claim 9 (currently amended): The method of claim 6, wherein the monoclonal antibody is a chimeric monoclonal antibody containing constant regions and variable regions from different species.

Claim 10 (original): The method of claim 6, wherein the monoclonal antibody is a humanized monoclonal antibody.

Claim 11 (canceled)

Claim 12 (new): The method of claim 1, wherein the gp39 antagonist is an anti-gp39 antibody or a gp39-binding fragment thereof, comprising variable regions of monoclonal antibody 24-31 or monoclonal antibody 89-76, or of an antibody having the gp39 binding characteristics thereof.

Claim 13 (new): The method of claim 12, wherein the gp39 antagonist is a gp39-binding antibody fragment comprising variable regions of monoclonal antibody 24-31.

Claim 14 (new): The method of claim 13, wherein the gp39-binding antibody fragment is a Fab or F(ab')₂ fragment comprising variable regions of monoclonal antibody 24-31.

B₃
Claim 15 (new): The method of claim 12, wherein the gp39 antagonist is a gp39-binding antibody fragment comprising variable regions of monoclonal antibody 89-76.

Claim 16 (new): The method of claim 15, wherein the gp39-binding antibody fragment is a Fab or F(ab')₂ fragment comprising variable regions of monoclonal antibody 89-76.

Claim 17 (new): The method of claim 9, wherein the chimeric monoclonal anti-gp39 antibody comprises variable regions of monoclonal antibody 24-31.

Claim 18 (new): The method of claim 9, wherein the chimeric monoclonal anti-gp39 antibody comprises variable regions of monoclonal antibody 89-76.

Claim 19 (new): The method of claim 10, wherein the humanized monoclonal anti-gp39 antibody comprises variable regions of monoclonal antibody 24-31.

Claim 20 (new): The method of claim 10, wherein the humanized monoclonal anti-gp39 antibody comprises variable regions of monoclonal antibody 89-76.